Page last updated: 2024-11-09

3-pyridinylboronic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3-pyridinylboronic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2734378
CHEMBL ID3236605
SCHEMBL ID4647
MeSH IDM000596800

Synonyms (62)

Synonym
AC-6170
3-pyridinylboronic acid, >=95.0%
1692-25-7
pyridine-3-boronic acid
pyridin-3-ylboronic acid
STK347187
3-pyridinylboronic acid
P1673
3-pyridylboronic acid
AKOS000264848
3-pyridineboronic acid ,
EN300-80761
(pyridin-3-yl)boronic acid
NCGC00249451-02
NCGC00249451-01
pyridin-3-yl-boronic acid
3-pyridineboronic
3-pyridinyl boronic acid
pyridin-3-yl-3-boronic acid
BP-10788
FT-0616373
AM20050870
boronic acid, b-3-pyridinyl-
PB14187
CHEMBL3236605
SCHEMBL4647
mfcd00674177
SY004445
AS-2593
pyridyl-3-boronic acid
pyridin-3-yl boronic acid
3-pyridyl-boronic acid
pyridine-3-yl boronic acid
3-pyridine-boronic acid
pyridine 3-boronic acid
3-pyridine boronic acid
3-pyridylboronicacid
pyridin-3-boronic acid
3-pyridineboric acid
pyridine-3-boronicacid
pyridine-3-boroni acid
pyridine 3-yl-boronic acid
(3-pyridinyl)boronic acid
3-pyridinyl-boronic acid
3-pyridyl boronic acid
(3-pyridyl)boronic acid
pyridine-3-yl-boronic acid
5-pyridineboronic acid
ABMYEXAYWZJVOV-UHFFFAOYSA-N
pyridine-3-ylboronic acid
Q-102225
boronic acid, 3-pyridinyl-
F1957-0039
DTXSID30370268
CS-D0809
Z608482642
BCP26402
BBL100315
OL10101
1,6-hexanebisphosphonicacid
pyridin-3-ylboronicacid
HY-75129
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1127995Toxicity in Staphylococcus aureus ATCC 25923 after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID1127993Toxicity in Staphylococcus aureus ATCC 25923 at 100 ug/ml after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID1127994Toxicity in fluoroquinolone-resistant Staphylococcus aureus 1199B expressing NorA at 100 ug/ml after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
AID1127992Inhibition of NorA in fluoroquinolone-resistant Staphylococcus aureus 1199B assessed as potentiation of 4 ug/ml of ciprofloxacin MIC at 100 ug/ml after 24 hrs by microdilution method2014Journal of medicinal chemistry, Mar-27, Volume: 57, Issue:6
First identification of boronic species as novel potential inhibitors of the Staphylococcus aureus NorA efflux pump.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's2 (28.57)24.3611
2020's2 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.33 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.73 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]